Data analysis on new molecular entities approved by FDA in 2017ZHANG Hua-ji, SUN Xiao-can, LIANG Yi, DING Li-xia, ZHU Feng-chang1697-1701
Analysis of patent protection situation of montelukast sodium in ChinaZHANG Jun-sheng, MA Qing-wen, ZHOU Zhong-yang, SHEN Qiang-yu1708-1713
The novel PARP inhibitor in recurrent ovarian cancer: niraparibHE Gai-yi-nan, JIAN Xiao-shun, YIN Yi-zi1714-1717
Enasidenib: a new drug for the treatment of acute myeloid leukaemiaYAN Li-li, MA Shuai, HUANG Li1718-1720
Dose exploration of retinoic acid induced multiple external abnormalities in ratsXIA Min-jie, MIAO Jian-cheng, WANG Yu-zhu, TIAN Fang, WANG Xiao-dong, DING Xun-cheng, LI Wei-hua, HU Jing-ying1726-1730
Isolation, identification and immunogenicity of various coxsackievirus A16 particlesGUO Hui-jie, LU Wei-wei, HAO Chun-sheng, MA Shu-hua, LIU Shao-hua, ZHANG Wei-qing, ZHAO Zhong-xiang, LI Xiu-ling1731-1736
Research development on pharmacokinetics and therapeutic drug monitoring of dasatinibLUO Xing-xian, HUANG Lin, ZHAO Hai-yan, XUE Xue-cai, HU Lei, YANG Chang-qing, FENG Wan-yu1737-1743
Advances in extraction, detection methods and pharmacological activities of Maca total alkaloidsDAI Hong-zhe, GAO Xu-chun, XU Wei-zhou, ZHAO Peng, FAN Jun, WEI Ya-hui1744-1752